HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in ...

Johnson & Johnson is looking to sell its Cerenovus stroke therapy business, according three unnamed people "with knowledge of ...

Johnson & Johnson MedTech (NYSE: JNJ) announced today that it launched the CereGlide 92 catheter system for treating acute ...

U.S. pharmaceutical company Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for at least $1 billion U.S. The sale is part of Johnson & Johnson’s ongoing efforts ...

Johnson & Johnson (NYSE:JNJ) is reportedly considering selling its stroke care unit, Cerenovus, in a deal that could value ...

Johnson & Johnson (NYSE:JNJ), the New Jersey-based healthcare company, is planning to sell its stroke care business, ...

Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

Johnson & Johnson has put its stroke care business up for sale, aiming for a valuation of more than $1bn, as part of its ...

Johnson & Johnson aims to streamline operations by selling its stroke care business, Cerenovus, valued at $1B+.

High-rolling investors have positioned themselves bearish on Johnson & Johnson JNJ, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other healthcare stocks. Healthcare stocks are widely considered a cornerstone of a retirement ...

Johnson & Johnson (Symbol: JNJ) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.2% yield ...